187 related articles for article (PubMed ID: 37113607)
1. The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study.
Zheng Q; Otahal P; Cox IA; de Graaff B; Campbell JA; Ahmad H; Walters EH; Palmer AJ
Front Med (Lausanne); 2023; 10():1157706. PubMed ID: 37113607
[TBL] [Abstract][Full Text] [Related]
2. Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database.
Agarwal P; Moshier E; Ru M; Ohri N; Ennis R; Rosenzweig K; Mazumdar M
Cancer Control; 2018; 25(1):1073274818789355. PubMed ID: 30021466
[TBL] [Abstract][Full Text] [Related]
3. Attention to Immortal Time Bias in Critical Care Research.
Vail EA; Gershengorn HB; Wunsch H; Walkey AJ
Am J Respir Crit Care Med; 2021 May; 203(10):1222-1229. PubMed ID: 33761299
[TBL] [Abstract][Full Text] [Related]
4. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies.
Tran T; Suissa S
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29724921
[TBL] [Abstract][Full Text] [Related]
5. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
[TBL] [Abstract][Full Text] [Related]
6. Immortal-time bias in older vs younger age groups: a simulation study with application to a population-based cohort of patients with colon cancer.
Pilleron S; Maringe C; Morris EJA; Leyrat C
Br J Cancer; 2023 Apr; 128(8):1521-1528. PubMed ID: 36759725
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study.
Leuschner G; Klotsche J; Kreuter M; Prasse A; Wirtz H; Pittrow D; Frankenberger M; Behr J; Kneidinger N;
Front Med (Lausanne); 2020; 7():601279. PubMed ID: 33313046
[No Abstract] [Full Text] [Related]
8. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
[TBL] [Abstract][Full Text] [Related]
9. Immortal Time Bias in National Cancer Database Studies.
Newman NB; Brett CL; Kluwe CA; Patel CG; Attia A; Osmundson EC; Kachnic LA
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):5-12. PubMed ID: 31404580
[TBL] [Abstract][Full Text] [Related]
10. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis.
Weberpals J; Jansen L; Carr PR; Hoffmeister M; Brenner H
Cancer Treat Rev; 2016 Jun; 47():1-11. PubMed ID: 27179912
[TBL] [Abstract][Full Text] [Related]
11.
Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
13. Distorting Effect of Immortal Time Bias on the Association Between Catheter Ablation for Atrial Fibrillation and Incident Stroke: Caveat Emptor.
Samuel M; Brophy JM; D'Aronco L; Tardif JC; Khairy P
Can J Cardiol; 2021 Mar; 37(3):377-381. PubMed ID: 32979508
[TBL] [Abstract][Full Text] [Related]
14. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
[TBL] [Abstract][Full Text] [Related]
15. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy.
Ishiwari M; Kono Y; Togashi Y; Kobayashi K; Kikuchi R; Kogami M; Abe S
Sarcoidosis Vasc Diffuse Lung Dis; 2024 Mar; 41(1):e2024002. PubMed ID: 38567555
[TBL] [Abstract][Full Text] [Related]
17. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.
Maddali MV; Moore AR; Sinha P; Newton CA; Kim JS; Adegunsoye A; Ma SF; Strek ME; Chen CH; Linderholm AL; Zemans RL; Moore BB; Wolters PJ; Martinez FJ; Rogers AJ; Raj R; Noth I; Oldham JM
Am J Respir Crit Care Med; 2024 Jun; ():. PubMed ID: 38913573
[No Abstract] [Full Text] [Related]
18. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.
Mi X; Hammill BG; Curtis LH; Lai EC; Setoguchi S
Stat Med; 2016 Nov; 35(26):4824-4836. PubMed ID: 27350312
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
[TBL] [Abstract][Full Text] [Related]
20. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
